Payment of Convertible Bond Installment
Avacta settled £2.55m principal and £0.414m interest on convertible bond following £3.25m equity placing.
- Convertible bond principal settled £2.55m
- Interest repayment £0.414m
- Remaining convertible bond principal £22.95m
- Equity placing announced £3.25m
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON and PHILADELPHIA - 21 July 2025 - Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that further to the announcement of the £3.25m equity financing on 17 July 2025 (the "Placing"), it has settled the quarterly principal of £2.55 million and interest repayment of c.£0.414 million in respect of the Company's unsecured convertible bond in cash. The Placing is due to complete on 24 July 2025.
After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £22.95 million.
| About the pre | CISION® Platform | |||
| The pre | CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre | CISION® platform harnesses this tumor specific protease to cleave pre | CISION® peptide drug conjugates and pre | CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.